Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bayer Files Larotrectinib In EU As LOXO-292 Hurtles Towards The Market

29 Aug 2018

• By Alexandra Shimmings

Cancer-cells-pink-color_1200x675

Related Content

Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer

14 Nov 2017

Loxo '292 And Cancer Drug Development Today: So Much Promise, So Many Questions

03 Jun 2018

Loxo Edges Closer To Commercial Market With Larotrectinib, But Diagnostic Challenge Persists

29 May 2018

Related Companies

Bayer AG

Loxo Oncology at Lilly

Additional Topics

Approvals Companies Cancer BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.